AURA: Aura Biosciences, Inc. - Summary | Jitta

Aura Biosciences, Inc.

NASDAQ:AURA

Price
$6.31
Loss Chance
58.9%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (0)
Recent Business Performance (17)
Financial Strength (32)
Return to Shareholders (0)
Competitive Advantage (1)
Jitta Signs
Cash Conversion CycleLess than 30 days
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
2.21
133.46%
3.05
146.31%
Biotechnology
5.68
36.42%
5.68
36.42%
6.36
42.59%
COMPANY DESCRIPTION
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.